What is the brivaracetam?

brivaracetam is , while it's Molecular Formula is C11H20 N2 O2. Brivaracetam, is a 4-n-propyl analog of levetiracetam (L331500), and a racetam derivative with anticonvulsant properties.

What is the CAS number for brivaracetam?

The CAS number of brivaracetam is 357336-20-0.

What is brivaracetam (357336-20-0) used for?

Brivaracetam, a novel oralantiepileptic drug with a high affinity for synaptic vesicleprotein 2A (SV2A), was approved in Europe and the US as anadjunctive therapy for the treatment of partial onset seizureswith or without secondary generalization in patients aged 16 orolder.42 Brivaracetam is very closely related to levetiracetam, anantiepileptic treatment whose immediate release formulationhas been available in the United States as a generic drug since2008, but whose extended release formulation is under patentprotection until 2028. The two drugs, which were bothdeveloped by UCB Pharma, are structurally similar withbrivaracetam having an n-propyl group at the C-4 position ofthe pyrrolidinone ring and levetiracetam having a hydrogen atthis same position. A systematic investigation of the varioussubstitutions of levetiracetam resulted in the identification ofmore potent and selective SV2A ligands and ultimatelyculminated in the discovery of brivaracetam, which has greateraffinity for SV2A, improved selectivity, more rapid brainpenetration, and faster onset of action against seizures thanlevetiracetam.

Product Class

357336-20-0

Product Name：Brivaracetam
Molecular Formula：C11H20 N2 O2
Purity：99%
Molecular Weight：212.292

Inquiry

Product Details:

CasNo： 357336-20-0

Molecular Formula： C11H20 N2 O2

Factory Supply High Purity Brivaracetam,Export 357336-20-0 Competitive Price

Molecular Formula:C11H20 N2 O2
Molecular Weight:212.292
Melting Point:76.38°
Boiling Point:409.3±28.0 °C(Predicted)
PKA:15.74±0.50(Predicted)
PSA：63.40000
Density:1.062
LogP:1.53710

Brivaracetam (Cas 357336-20-0) Usage

Brivaracetam is a medication utilized alone or in combination with other drugs to manage partial onset seizures in adults, children, and infants aged 1 month and older. Belonging to the class of anticonvulsants, Brivaracetam is employed to help control partial onset seizures in the treatment of epilepsy. While it cannot cure epilepsy, it effectively works to regulate seizures for as long as the patient continues to use it. Brivaracetam is available only with a doctor's prescription.

357336-20-0 Relevant articles

Chiral resolution method of brivaracetam

-

Paragraph 0038-0042; 0049-0051; 0058-0060, (2022/01/12)

The invention relates to a chiral resolu...

Preparation methods of brivaracetam and intermediate thereof

-

Paragraph 0077-0078, (2021/11/03)

The invention discloses a preparation me...

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males

Maria Laura Sargentini-Maier, Paul Rolan, John Connell, Dominique Tytgat, Tom Jacobs, Etienne Pigeolet, Jean-Michel Riethuisen, Armel Stockis

British Journal of Clinical Pharmacology, Volume63, Issue6 June 2007 Pages 680-688

Studies to evaluate the pharmacological profile of brivaracetam demonstrate an approximately 10-fold higher potency than levetiracetam as well as a higher efficacy in models of epilepsy.

357336-20-0 Process route

: (2S)-2-[(4R)-2-oxo-4-n-propyl-1-pyrrolidinyl]butyric acid

: 357336-20-0,357336-99-3,943986-70-7
brivaracetam

Conditions

Conditions	Yield
With ammonium chloride; N-ethyl-N,N-diisopropylamine; HATU; In tetrahydrofuran; at 20 ℃; for 2h; Time; Large scale;	90%
With ammonia; pivaloyl chloride; triethylamine; In dichloromethane; at 0 - 10 ℃; for 6h; Inert atmosphere;	88%
(2S)-2-[(4R)-2-oxo-4-n-propyl-1-pyrrolidinyl]butyric acid; With chloroformic acid ethyl ester; triethylamine; In dichloromethane; at -10 - -5 ℃; for 1h; With ammonium bicarbonate; In dichloromethane; at -10 - -5 ℃;	67%
With pyridine; di-tert-butyl dicarbonate; ammonium bicarbonate; In 1,4-dioxane; at 20 ℃; for 12h;	63%
(2S)-2-[(4R)-2-oxo-4-n-propyl-1-pyrrolidinyl]butyric acid; With thionyl chloride; In dichloromethane; at 0 ℃; for 0.5h; With ammonia; In dichloromethane; for 6h; Reagent/catalyst;	33 g
Multi-step reaction with 2 steps 1: thionyl chloride / 20 h / 20 °C 2: ammonia / tetrahydrofuran / 20 h / 20 °C With thionyl chloride; ammonia; In tetrahydrofuran;
With ammonium chloride; N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In tetrahydrofuran; at 20 ℃; for 2h;	7 g

: isopropyl (2S)-2-[(4R)-2-oxo-4-propyl-1-pyrrolidinyl]butyrate

: 357336-20-0,357336-99-3,943986-70-7
brivaracetam